These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9179693)

  • 1. Screening of H-ras gene point mutations in 50 cases of bladder carcinoma.
    Saito S; Hata M; Fukuyama R; Sakai K; Kudoh J; Tazaki H; Shimizu N
    Int J Urol; 1997 Mar; 4(2):178-85. PubMed ID: 9179693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of H-ras gene point mutations in transitional cell carcinoma of human urinary bladder using polymerase chain reaction.
    Saito S
    Keio J Med; 1992 Jun; 41(2):80-6. PubMed ID: 1619852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A PCR-RFLP method for the detection of activated H-ras oncogene with a point mutation at codon 12 and 61.
    Hong SJ; Lee T; Park YS; Lee KO; Chung BH; Lee SH
    Yonsei Med J; 1996 Dec; 37(6):371-9. PubMed ID: 9048488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated H-ras gene mutations in transitional cell carcinoma of urinary bladder in a Kashmiri population.
    Pandith AA; Shah Z; Rasool R; Dil-Afroze ; Yousuf A; Parveen N; Wani S; Siddiqi M
    Tumori; 2010; 96(6):993-8. PubMed ID: 21388064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of RAS family genes in urothelial carcinoma.
    Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
    J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of a rare point mutation in Ki-ras of a human bladder cancer xenograft by polymerase chain reaction and direct sequencing.
    Grimmond SM; Raghavan D; Russell PJ
    Urol Res; 1992; 20(2):121-6. PubMed ID: 1553789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of RAS gene family in specimens of bladder cancer.
    Karimianpour N; Mousavi-Shafaei P; Ziaee AA; Akbari MT; Pourmand G; Abedi A; Ahmadi A; Afshin Alavi H
    Urol J; 2008; 5(4):237-42. PubMed ID: 19101897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of H-ras mutations in human bladder cancer detected by direct sequencing.
    Burchill SA; Neal DE; Lunec J
    Br J Urol; 1994 May; 73(5):516-21. PubMed ID: 8012773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Point mutations of c-ras genes in human bladder cancer and kidney cancer.
    Nagata Y; Abe M; Kobayashi K; Saiki S; Kotake T; Yoshikawa K; Ueda R; Nakayama E; Shiku H
    Jpn J Cancer Res; 1990 Jan; 81(1):22-7. PubMed ID: 2108944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection and clinical pathological significance of the expression of P21, P185, p53 proteins and mutation of ras, p53 genes in transitional cell carcinoma of the bladder].
    Yu D; Liu F; Liang Z
    Zhonghua Bing Li Xue Za Zhi; 1996 Aug; 25(4):202-5. PubMed ID: 9275651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequencing analysis of Ha-, Ki-, and N-ras genes in rat urinary bladder tumors induced by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide (FANFT) and sodium saccharin.
    Masui T; Mann AM; Borgeson CD; Garland EM; Okamura T; Fujii H; Pelling JC; Cohen SM
    Teratog Carcinog Mutagen; 1993; 13(5):225-33. PubMed ID: 7905676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Point mutation in codons 12 and 61 of the Ha-ras gene in rat urinary bladder carcinomas induced by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide.
    Masui T; Mann AM; Garland EM; Okamura T; Johansson PL; Cohen SM
    Mol Carcinog; 1990; 3(4):210-5. PubMed ID: 2206284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Low incidence of mutations in codon 12 of the c-K-ras gene in bladder cancer].
    Ejarque MJ; Villanueva A; Chechile G; Regalado R; Errando C; Algaba F; Capella G; Lluis F; Villavicencio H; Vicente J
    Actas Urol Esp; 1995 Sep; 19(8):599-603. PubMed ID: 8669326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. H-ras mutations in rat urinary bladder carcinomas induced by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide and sodium saccharin, sodium ascorbate, or related salts.
    Masui T; Mann AM; Macatee TL; Okamura T; Garland EM; Fujii H; Pelling JC; Cohen SM
    Cancer Res; 1991 Jul; 51(13):3471-5. PubMed ID: 2054786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H-ras activation and ras p21 expression in bladder tumors induced in F344/NCr rats by N-butyl-N-(4-hydroxybutyl)nitrosamine.
    Enomoto T; Ward JM; Perantoni AO
    Carcinogenesis; 1990 Dec; 11(12):2233-8. PubMed ID: 2265474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. H-ras oncogene point mutations in arthritic synovium.
    Roivainen A; Jalava J; Pirilä L; Yli-Jama T; Tiusanen H; Toivanen P
    Arthritis Rheum; 1997 Sep; 40(9):1636-43. PubMed ID: 9324018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers.
    Przybojewska B; Jagiello A; Jalmuzna P
    Cancer Genet Cytogenet; 2000 Aug; 121(1):73-7. PubMed ID: 10958945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ras oncogene point mutations in bladder cancer resistant to cisplatin.
    Wood DP; Anderson AE; Fair R; Chaganti RS
    Urol Res; 1992; 20(4):313-6. PubMed ID: 1509639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening of human bladder carcinomas for the presence of Ha-ras codon 12 mutation.
    Cattan N; Saison-Behmoaras T; Mari B; Mazeau C; Amiel JL; Rossi B; Gioanni J
    Oncol Rep; 2000; 7(3):497-500. PubMed ID: 10767358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. K-RAS mutation in transitional cell carcinoma of urinary bladder.
    Ayan S; Gokce G; Kilicarslan H; Ozdemir O; Yildiz E; Gultekin EY
    Int Urol Nephrol; 2001; 33(2):363-7. PubMed ID: 12092657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.